

Listing of Amended Claims:

1-36. (Canceled)

37. (Currently amended) An isolated polypeptide comprising the amino acid sequence ~~eonsisting~~ of SEQ ID NO:107.

38. (Currently amended) A fusion protein comprising a first polypeptide comprising the amino acid sequence of SEQ ID NO:107 according to claim 37 and a second polypeptide.

39. (Currently amended) A pharmaceutical composition comprising a polypeptide of claim 37 ~~or a fusion protein of claim 38; and a physiologically acceptable carrier~~.

40. (Original) The composition of claim 39, further comprising a non-specific immune response enhancer.

41. (Original) The composition of claim 40, wherein the non-specific immune response enhancer is an adjuvant.

42-55. (Canceled)

56. (Currently amended) An isolated polypeptide ~~eomprising the amino acid sequence consisting of SEQ ID NO:107 or~~ comprising an immunogenic fragment of SEQ ID NO:107, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length.

57. (Currently amended) A fusion protein comprising a first polypeptide comprising an immunogenic fragment of SEQ ID NO:107, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length according to claim 56 and a second polypeptide.

58. (Currently amended) A pharmaceutical composition comprising a polypeptide of claim 56 ~~or a fusion protein of claim 57; and a physiologically acceptable carrier~~.

59. (Previously presented) The composition of claim 58, further comprising a non-specific immune response enhancer.

60. (New) The composition of claim 59, wherein the non-specific immune response enhancer is an adjuvant.

61. (New) A fusion protein according to claim 38, where said second polypeptide is an *M. tuberculosis* antigen.

62. (New) A pharmaceutical composition comprising a fusion protein of claim 38.

63. (New) The pharmaceutical composition of claim 62, further comprising a non-specific immune response enhancer.

64. (New) The pharmaceutical composition of claim 63, wherein the non-specific immune response enhancer is an adjuvant.

65. (New) A fusion protein according to claim 57, where said second polypeptide is an *M. tuberculosis* antigen.

66. (New) A pharmaceutical composition comprising a fusion protein of claim 57.

67. (New) The pharmaceutical composition of claim 66, further comprising a non-specific immune response enhancer.

68. (New) The composition of claim 67, wherein the non-specific immune response enhancer is an adjuvant.

69. (New) An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:107.

70. (New) A fusion protein comprising a first polypeptide consisting of the amino acid sequence of SEQ ID NO:107 and a second polypeptide.

71. (New) A fusion protein according to claim 70, where said second polypeptide is an *M. tuberculosis* antigen.
72. (New) A pharmaceutical composition comprising a polypeptide of claim 69.
73. (New) A pharmaceutical composition comprising a fusion protein of claim 70.
74. (New) The pharmaceutical composition of claim 72, further comprising a non-specific immune response enhancer.
75. (New) The pharmaceutical composition of claim 74, wherein the non-specific immune response enhancer is an adjuvant.
76. (New) The pharmaceutical composition of claim 73, further comprising a non-specific immune response enhancer.
77. (New) The pharmaceutical composition of claim 76, wherein the non-specific immune response enhancer is an adjuvant.
78. (New) An isolated polypeptide consisting of an immunogenic fragment of SEQ ID NO:107, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length.
79. (New) A fusion protein comprising a first polypeptide consisting of an immunogenic fragment of SEQ ID NO:107, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length, and a second polypeptide.
80. (New) A fusion protein according to claim 79, where said second polypeptide is an *M. tuberculosis* antigen.
81. (New) A pharmaceutical composition comprising a polypeptide of claim 78.

82. (New) A pharmaceutical composition comprising a fusion protein of claim 79.

83. (New) The pharmaceutical composition of claim 81, further comprising a non-specific immune response enhancer.

84. (New) The pharmaceutical composition of claim 83, wherein the non-specific immune response enhancer is an adjuvant.

85. (New) The pharmaceutical composition of claim 82, further comprising a non-specific immune response enhancer.

86. (New) The pharmaceutical composition of claim 85, wherein the non-specific immune response enhancer is an adjuvant.